Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients

Bone Marrow Transplantation

Volumn 46, Issue 8, 2011, Pages 1113-1117

  Onizuka, M ^a   Kunii, N ^a   Toyosaki, M ^a   MacHida, S ^a   Ohgiya, D ^a   Ogawa, Y ^a   Kawada, H ^a   Inoko, H ^a   Ando, K ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

calcineurin inhibitor; CYP3A5; MDR1; polymorphism

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 3A5 GENE; CYTOCHROME P450 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; JAPANESE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; P GLYCOPROTEIN GENE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CALCINEURIN; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 80051675148     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.273     Document Type: Article

References (20)

1. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115.
2. Mayer AD, Dmitrewski J, Squifflet J-P, Besse T, Grabensee B, Klein B et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443. (Pubitemid 27349884)
3. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537. (Pubitemid 36159889)
4. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391. (Pubitemid 32268418)
5. Hesselink DA, van Schaik RHN, van der Heiden IP, van der Werf M, Gregoor PJHS, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclospor-ine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254. (Pubitemid 37083100)
6. Hesselink DA, van Gelder T, van Schaik RH. The pharma-cogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005; 6: 323-337. (Pubitemid 40916357)
7. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33. (Pubitemid 38130115)
8. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154. (Pubitemid 38373108)
9. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433. (Pubitemid 38534563)
10. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
11. Elmaagacli AH, Koldehoff M, Steckel NK, Trenschel R, Ottinger H, Beelen DW. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 2007; 40: 659-664. (Pubitemid 47456480)
12. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharma-cokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141-175.
13. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
14. Tan S-H, Lee S-C, Goh B-C, Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008; 14: 8027-8041.
15. Dai Z, Papp A, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1: 24.
16. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-439. (Pubitemid 26380099)
17. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
18. Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther 2009; 35: 121-124.
19. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009; 44: 371-374.
20. Chang HH, Lee NY, Ko WC, Lee HC, Yang YH, Wu CJ et al. Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis. Int J Infect Dis 2010; 14: e348-e350.